Amedisys (NASDAQ:AMED) reported Q4 EPS of $1.16, $0.18 better than the analyst estimate of $0.98. Revenue for the quarter came in at $62 million versus the consensus estimate of $560.59 million.
GUIDANCE:
Amedisys sees FY2023 EPS of $4.13-$4.36, versus the consensus of $4.86. Amedisys sees FY2023 revenue of $2.244-2.274 billion, versus the consensus of $2.36 billion.